Are you a CIPA member?
Sign in to your account to register for the event
If you are not yet registered or a member of CIPA, please register here
- News
- News
- NewsMedia
- Events
- Events
- EventsIntroductory Patent Paralegal CourseAdvanced Patent Paralegal Course (APPC)
- Advice
- Advice
- IP explainedResources
- Members
- Members
- MembershipBrand & Marketing Materials
- Publications
- Publications
- Online ShopCIPA JournalDownloads
- Jobs
- About Us
×Event Listing
Understanding and combating obviousness rejections under 35 U.S.C. 103 before the USPTO
18Feb
Webinar Understanding and combating obviousness rejections under 35 U.S.C. 103 before the USPTO
Thursday 18 February
Location
Obviousness rejections are ubiquitous when dealing with the USPTO. Although they are commonplace in examination, it can be difficult to clearly identify the Examiner’s concerns reflected in the rejection and to plot a path to patentable claims. Our discussion will focus on these rejections with suggestions for overcoming them and working with your Examiner to find a way forward.
Audience
All
Speakers
Loren Hulse, Holland & HartLoren Hulse, Holland & Hart
As a practitioner, Loren has developed, managed, and protected both large and small domestic and foreign patent and trademark portfolios. His wide-ranging biotech and pharmaceutical experience includes advising clients how to protect small molecule and peptide drugs, methods of treatment, genetic constructs and therapies, nucleotide analogs, and RNA related drug technologies. He has also counseled clients developing medical devices such as optically-guided feeding tubes, injectors, diagnostic kits, catheters, and cardiac assist devices. In the chemical arena, Loren’s experience includes assisting clients to protect solid oxide fuel cell technologies, ionically-conductive membrane applications, and syngas production techniques.
Shopping Bag (0)